Evotec SE reports results for the first nine months 2021 and provides corporate update
More detailed information and financial tables are available in our nine-month report published on the Evotec website under the following link:?1) Adjusted for negative exchange rate effects of ? 11.2 m, Group revenues amount to ? 442.1 m2) Of which unpartnered R&D expenses of ? 42.6 m in 9M 2021 (9M 2020: ? 33.4 m)3) Before changes in contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result4) Revenues from material recharges of ? 23.6 m are allocated to EVT Execute as of 9M 2021 5) Revenues from material recharges of ? 1.2m are allocated to EVT Innovate as of 9M 2021
WEBCAST / CONFERENCE CALL
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.
Conference call details Date: Thursday, 11 November 2021 Time: 02.00 pm CET (08.00 am ET, 01.00 pm GMT)
From Germany: +49 69 20 17 44 220 From France: +33 170 709 502 From Italy: +39 023 600 6663 From Switzerland: +41 445 806 522 From UK: +44 20 3009 2470 From USA: +1 877 423 0830 Access Code: 82123163#
A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec20211111/no-audio.
Webcast details To join the audio webcast and to access the presentation slides you will find a link on our homepage http://www.evotec.com shortly before the event.
A replay of the conference call will be available for seven days and can be accessed from Germany by dialling +49 69 201744221, from UK by dialling +44 20 3364 5150 and from USA by dialling +1 (844) 307-9362.
The access code is 315614529#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/en/investor-relations/publications and under the direct link https://www.webcast-eqs.com/evotec20211111.
ABOUT EVOTEC SEEvotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.
FORWARD-LOOKING STATEMENTS This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.IR Contact Evotec SE: Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, firstname.lastname@example.org ?
11.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.dgap.deLanguage: English Company: Evotec SE Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg
Germany Phone: +49 (0)40 560 81-0 Fax: +49 (0)40 560 81-222 E-mail: email@example.com Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Indices: MDAX, TecDAX Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1248088 ? End of News DGAP News Service